受强制性开放获取政策约束的文章 - Arushi Khurana了解详情
无法在其他位置公开访问的文章：1 篇
SINGLE CELL ANALYSIS REVEALS IMMUNE DYSFUNCTION IN LARGE B CELL LYMPHOMA (LBCL) PTS WITH HYPOMAGNESEMIA RECEIVING AXI‐CEL: RESULTS FROM ZUMA‐1 TRIAL AND MAYO CLINIC COHORT.
P Mondello, J Gile, Z Wang, Y Li, R Bansal, S Gandhi, H Zhang, E Babadi, ...
Hematological Oncology 41, 2023
强制性开放获取政策： US National Institutes of Health, Lymphoma Research Foundation, USA
可在其他位置公开访问的文章：14 篇
Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review
EJ Bataillard, CY Cheah, MJ Maurer, A Khurana, TA Eyre, TC El-Galaly
Blood advances 5 (9), 2426-2437, 2021
强制性开放获取政策： US National Institutes of Health, National Institute for Health Research, UK …
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
S Gouni, AC Rosenthal, JL Crombie, A Ip, MK Kamdar, B Hess, L Feng, ...
Blood Advances 6 (9), 2757-2762, 2022
强制性开放获取政策： US National Institutes of Health, Lymphoma Research Foundation, USA
Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era
A Khurana, M Novo, GS Nowakowski, KM Ristow, RJ Spinner, CH Hunt, ...
Blood advances 5 (5), 1379-1387, 2021
强制性开放获取政策： US National Institutes of Health
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
DA Qualls, N Lambert, PF Caimi, M Merrill, P Pullarkat, RC Godby, ...
Blood 142 (26), 2327-2331, 2023
强制性开放获取政策： US National Institutes of Health, Lymphoma Research Foundation, USA
Impact of organ function–based clinical trial eligibility criteria in patients with diffuse large B-cell lymphoma: who gets left behind?
A Khurana, R Mwangi, GS Nowakowski, TM Habermann, SM Ansell, ...
Journal of Clinical Oncology 39 (15), 1641-1649, 2021
强制性开放获取政策： US National Institutes of Health
Analysis and impact of a multidisciplinary lymphoma virtual tumor board
TM Habermann, A Khurana, R Lentz, JJ Schmitz, AG von Bormann, ...
Leukemia & lymphoma 61 (14), 3351-3359, 2020
强制性开放获取政策： US National Institutes of Health
Clinicopathologic characteristics, treatment, and outcomes of post-transplant lymphoproliferative disorders: a single-institution experience using 2017 WHO diagnostic criteria
RL King, A Khurana, R Mwangi, A Fama, KM Ristow, MJ Maurer, ...
Hemasphere 5 (10), e640, 2021
强制性开放获取政策： US National Institutes of Health
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
AM Tun, A Khurana, R Mwangi, BK Link, Y Wang, AL Feldman, ...
Blood advances 6 (17), 5210-5221, 2022
强制性开放获取政策： US National Institutes of Health
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
RE Steiner, SR Hwang, A Khurana, TM Habermann, N Epperla, ...
Blood Advances 7 (24), 7485-7493, 2023
强制性开放获取政策： US Department of Defense, US National Institutes of Health, National …
Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy
Z Xie, T Lasho, A Khurana, A Ferrer, C Finke, AA Mangaonkar, S Ansell, ...
Haematologica 109 (2), 509, 2023
强制性开放获取政策： US National Institutes of Health
Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
A Khurana, R Mwangi, LJ Nastoupil, PM Reagan, U Farooq, JT Romancik, ...
Blood 140 (Supplement 1), 2056-2058, 2022
强制性开放获取政策： US National Institutes of Health
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
A Khurana, R Mwangi, SM Ansell, TM Habermann, JR Cerhan, C Strouse, ...
Blood cancer journal 11 (7), 133, 2021
强制性开放获取政策： US National Institutes of Health
Cumulative incidence, predictors, and outcomes of transformation to diffuse large B-cell lymphoma in a prospective cohort of patients with marginal zone lymphoma
C Bommier, BK Link, B Gysbers, MJ Maurer, MC Larson, A Khurana, ...
Blood 142, 1672, 2023
强制性开放获取政策： National Institute of Health and Medical Research, France
LEO Consortium for Real World Evidence (CReWE): Outcomes after Second-Line Therapy in Large B-Cell Lymphoma By Treatment Era
JL Koff, MC Larson, P Martin, JB Cohen, SR Ayyappan, BK Link, ...
Blood 142, 307, 2023
强制性开放获取政策： Cancer Prevention Research Institute of Texas, USA
出版信息和资助信息由计算机程序自动确定